Bronwyn D Mixter (Bronwyn Mixter)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 13

Top Topics

Pluripotent Stem Cells

Epidermal Growth Factor Receptor

Drug Administration

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Cancer discovery

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Mirat Shah, Hima Lingam, Xin Gao, Haley Gittleman, Mallorie H Fiero, Danielle Krol, Nikolett Biel, Tiffany K Ricks, Wentao Fu, Salaheldin Hamed, Fang Li, Jillian Jielin Sun, Jianghong Fan, Robert N Schuck, Manuela Grimstein, Liuya Tang, Shyam Kalavar, Abdelrahmman Abukhdeir, Anand Pathak, Soma Ghosh, Ilynn Bulatao, Amy Tilley, William F Pierce, Bronwyn D Mixter, Shenghui Tang, Richard Pazdur, Paul Kluetz, Laleh Amiri-Kordestani
US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1 -Mutated Advanced or Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Mirat Shah, Hima Lingam, Xin Gao, Haley Gittleman, Mallorie H Fiero, Danielle Krol, Nikolett Biel, Tiffany K Ricks, Wentao Fu, Salaheldin Hamed, Fang Li, Jillian Jielin Sun, Jianghong Fan, Robert N Schuck, Manuela Grimstein, Liuya Tang, Shyam Kalavar, Abdelrahmman Abukhdeir, Anand Pathak, Soma Ghosh, Ilynn Bulatao, Amy Tilley, William F Pierce, Bronwyn D Mixter, Shenghui Tang, Richard Pazdur, Paul Kluetz, Laleh Amiri-Kordestani
US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1 -Mutated Advanced or Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (10) (2024)
Asma Dilawari, James Buturla, Christy Osgood, Xin Gao, Wei Chen, Tiffany K Ricks, Timothy Schaefer, Sreedevi Avasarala, Francisca Reyes Turcu, Anand Pathak, Shyam Kalavar, Vishal Bhatnagar, Justin S Collazo, Nam Atiqur Rahman, Bronwyn D Mixter, Shenghui Tang, Richard Pazdur, Paul Kluetz, Laleh Amiri-Kordestani
US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA / AKT1 / PTEN Alterations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Mirat Shah, Hima Lingam, Xin Gao, Haley Gittleman, Mallorie H Fiero, Danielle Krol, Nikolett Biel, Tiffany K Ricks, Wentao Fu, Salaheldin Hamed, Fang Li, Jillian Jielin Sun, Jianghong Fan, Robert N Schuck, Manuela Grimstein, Liuya Tang, Shyam Kalavar, Abdelrahmman Abukhdeir, Anand Pathak, Soma Ghosh, Ilynn Bulatao, Amy Tilley, William F Pierce, Bronwyn D Mixter, Shenghui Tang, Richard Pazdur, Paul Kluetz, Laleh Amiri-Kordestani
US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1 -Mutated Advanced or Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (10) (2024)
Joshua M Donaldson, Marjilla Seddiq, Michael J Fusco, Shyamli Singla, Gulsum E Pamuk, Rosa J Lee-Alonso, Bronwyn D Mixter, Kirsten B Goldberg, Laleh Amiri-Kordestani, R Angelo de Claro, Nicole Drezner, Nicole J Gormley, Bindu Kanapuru, Steven J Lemery, Lola A Fashoyin-Aje, Nicholas C Richardson, Harpreet Singh, Daniel L Suzman, Marc R Theoret, Paul G Kluetz, Richard Pazdur
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development. Cancer discovery 13 (12) (2023)
Joshua M Donaldson, Marjilla Seddiq, Michael J Fusco, Shyamli Singla, Gulsum E Pamuk, Rosa J Lee-Alonso, Bronwyn D Mixter, Kirsten B Goldberg, Laleh Amiri-Kordestani, R Angelo de Claro, Nicole Drezner, Nicole J Gormley, Bindu Kanapuru, Steven J Lemery, Lola A Fashoyin-Aje, Nicholas C Richardson, Harpreet Singh, Daniel L Suzman, Marc R Theoret, Paul G Kluetz, Richard Pazdur
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development. Cancer discovery 13 (12) (2023)
Oladimeji Akinboro, Nicole Drezner, Anup Amatya, Jin Runyan, Jeanne Fourie-Zirkelbach, Miao Zhao, Youwei Bi, Kwadwo Korsah, Bronwyn D Mixter, Shenghui Tang, Erin Larkins, Richard Pazdur, Julia A Beaver, Harpreet Singh
US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Joshua M Donaldson, Marjilla Seddiq, Michael J Fusco, Shyamli Singla, Gulsum E Pamuk, Rosa J Lee-Alonso, Bronwyn D Mixter, Kirsten B Goldberg, Laleh Amiri-Kordestani, R Angelo de Claro, Nicole Drezner, Nicole J Gormley, Bindu Kanapuru, Steven J Lemery, Lola A Fashoyin-Aje, Nicholas C Richardson, Harpreet Singh, Daniel L Suzman, Marc R Theoret, Paul G Kluetz, Richard Pazdur
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development. Cancer discovery 13 (12) (2023)
Asma Dilawari, Mirat Shah, Gwynn Ison, Haley Gittleman, Mallorie H Fiero, Ankit Shah, Salaheldin S Hamed, Junshan Qiu, Jingyu Yu, Wimolnut Manheng, Tiffany K Ricks, Rajan Pragani, Arulvathani Arudchandran, Paresma Patel, Shadia Zaman, Arpita Roy, Shyam Kalavar, Soma Ghosh, William F Pierce, Nam Atiqur Rahman, Shenghui Tang, Bronwyn D Mixter, Paul G Kluetz, Richard Pazdur, Laleh Amiri-Kordestani
FDA Approval Summary: Mirvetuximab soravtansine-gynx for FRα-positive, Platinum-Resistant Ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Joshua M Donaldson, Marjilla Seddiq, Michael J Fusco, Shyamli Singla, Gulsum E Pamuk, Rosa J Lee-Alonso, Bronwyn D Mixter, Kirsten B Goldberg, Laleh Amiri-Kordestani, R Angelo de Claro, Nicole Drezner, Nicole J Gormley, Bindu Kanapuru, Steven J Lemery, Lola A Fashoyin-Aje, Nicholas C Richardson, Harpreet Singh, Daniel L Suzman, Marc R Theoret, Paul G Kluetz, Richard Pazdur
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development. Cancer discovery 13 (12) (2023)
Elizabeth S Duke, Michael J Fusco, Patrick DeMoss, Asma Dilawari, Gulsum E Pamuk, Jessica Boehmer, Bronwyn D Mixter, Kirsten B Goldberg, Paul G Kluetz, Richard Pazdur
Highlights of FDA Oncology Approvals in 2022: Tissue-Agnostic Indications, Dosage Optimization, and Diversity in Drug Development. Cancer discovery 12 (12) (2022)
Mirat Shah, Christy L Osgood, Anup K Amatya, Mallorie H Fiero, William F Pierce, Abhilasha Nair, Jonathan Herz, Kim J Robertson, Bronwyn D Mixter, Shenghui Tang, Richard Pazdur, Julia A Beaver, Laleh Amiri-Kordestani
FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Melanie E Royce, Christy Osgood, Flora Mulkey, Erik Bloomquist, William F Pierce, Arpita Roy, Shyam Kalavar, Soma Ghosh, Reena Philip, Fatima Rizvi, Bronwyn D Mixter, Shenghui Tang, Richard Pazdur, Julia A Beaver, Laleh Amiri-Kordestani
FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (11) (2022)